Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd